{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:13:45Z","timestamp":1783098825952,"version":"3.54.6"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001350","name":"Government of Singapore Ministry of Health","doi-asserted-by":"publisher","award":["MOH-STaR24jan-0004"],"award-info":[{"award-number":["MOH-STaR24jan-0004"]}],"id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.smim.2025.102004","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T22:27:12Z","timestamp":1762468032000},"page":"102004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness"],"prefix":"10.1016","volume":"80","author":[{"given":"Shan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-0485","authenticated-orcid":false,"given":"Antonio","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2025.102004_bib1","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2018.12.001","article-title":"The trends in incidence of primary liver cancer caused by specific etiologies: results from the global burden of disease study 2016 and implications for liver cancer prevention","volume":"70","author":"Liu","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.smim.2025.102004_bib2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.smim.2025.102004_bib3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.smim.2025.102004_bib4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/SLA.0000000000001556","article-title":"A review and update of treatment options and controversies in the management of hepatocellular carcinoma","volume":"263","author":"Dhir","year":"2016","journal-title":"Ann. Surg."},{"key":"10.1016\/j.smim.2025.102004_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.smim.2025.102004_bib6","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2025.102004_bib7","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2024.0469","article-title":"Engineering HBV-specific T cells for treatment of HBV-related HCC and HBV infection: past, present and future","author":"Bertoletti","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.smim.2025.102004_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.86","article-title":"Toward \u201coff-the-shelf\u201d allogeneic CAR T cells","volume":"3","author":"Aftab","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.smim.2025.102004_bib9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","article-title":"Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma","volume":"31","author":"Quintarelli","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2025.102004_bib10","first-page":"1","article-title":"In vivo CAR engineering for immunotherapy","author":"Li","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2025.102004_bib11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.04.045","article-title":"Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma","volume":"137","author":"Gehring","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.smim.2025.102004_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","article-title":"Immunological landscape and immunotherapy of hepatocellular carcinoma","volume":"12","author":"Prieto","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.smim.2025.102004_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nbt.4090","article-title":"Driving T-cell immunotherapy to solid tumors","volume":"36","author":"Garber","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.smim.2025.102004_bib14","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2025.102004_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.smim.2025.102004_bib16","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng.3547","article-title":"Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer","volume":"48","author":"Fujimoto","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.smim.2025.102004_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/v9040075","article-title":"HBV DNA integration: molecular mechanisms and clinical implications","volume":"9","author":"Tu","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.smim.2025.102004_bib18","doi-asserted-by":"crossref","first-page":"25075","DOI":"10.18632\/oncotarget.25308","article-title":"Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers","volume":"9","author":"Furuta","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.smim.2025.102004_bib19","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1172\/JCI66043","article-title":"Mobilizing monocytes to cross-present circulating viral antigen in chronic infection","volume":"123","author":"Gehring","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.smim.2025.102004_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/cr.2018.11","article-title":"Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing","volume":"28","author":"Duan","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.smim.2025.102004_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.smim.2025.102004_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.165","article-title":"The significance of intertumor and intratumor heterogeneity in liver cancer","volume":"50","author":"Liu","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.smim.2025.102004_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.smim.2025.102004_bib24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1172\/JCI31446","article-title":"Principles of adoptive T cell cancer therapy","volume":"117","author":"June","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.smim.2025.102004_bib25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2025.102004_bib26","first-page":"1","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","author":"Locatelli","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2025.102004_bib27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nri2635","article-title":"Engineering lymphocyte subsets: tools, trials and tribulations","volume":"9","author":"June","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2025.102004_bib28","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191663","article-title":"Challenges of CAR- and TCR-T cell-based therapy for chronic infections","volume":"217","author":"Bertoletti","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2025.102004_bib29","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1053\/j.gastro.2019.01.251","article-title":"Use of expression profiles of hbv-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy","volume":"156","author":"Tan","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.smim.2025.102004_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032716","article-title":"Proteogenomic identification of Hepatitis B virus (HBV) genotype-specific HLA-I restricted peptides from HBV-positive patient liver tissues","volume":"13","author":"Srivastava","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.102004_bib31","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/liv.12807","article-title":"Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma","author":"Saitta","year":"2015","journal-title":"Liver Intern. 35"},{"key":"10.1016\/j.smim.2025.102004_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines","volume":"55","author":"Gehring","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.smim.2025.102004_bib33","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1038\/srep04166","article-title":"Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections","volume":"4","author":"Banu","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2025.102004_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182936","article-title":"Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use","volume":"12","author":"Wisskirchen","year":"2017","journal-title":"PLOS One"},{"key":"10.1016\/j.smim.2025.102004_bib35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.omtm.2021.10.012","article-title":"Characterization of a library of 20 HBV-specific MHC class II-restricted T cell receptors","volume":"23","author":"Schreiber","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.smim.2025.102004_bib36","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1172\/JCI93024","article-title":"Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection","volume":"127","author":"Kah","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.smim.2025.102004_bib37","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1172\/JCI120228","article-title":"T cell receptor grafting allows virological control of Hepatitis B virus infection","volume":"129","author":"Wisskirchen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.smim.2025.102004_bib38","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.7150\/jca.26052","article-title":"Molecular Characterization of HBV DNA integration in patients with hepatitis and hepatocellular carcinoma","volume":"9","author":"Yang","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.smim.2025.102004_bib39","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s12072-023-10524-x","article-title":"Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial","volume":"17","author":"Yang","year":"2023","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.smim.2025.102004_bib40","article-title":"Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells","volume":"5","author":"Aggarwal","year":"2022","journal-title":"J. Hep. Rep."},{"key":"10.1016\/j.smim.2025.102004_bib41","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","article-title":"Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load","volume":"75","author":"Meier","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.smim.2025.102004_bib42","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.smim.2025.102004_bib43","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1158\/1078-0432.CCR-25-1245","article-title":"HBV-specific TCR\u2013T cell therapy combining mRNA electroporation and lentiviral transduction: treatment regimen for recurrent HBV-Related HCC after liver transplantation","volume":"31","author":"Zhao","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2025.102004_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01457-18","article-title":"Spatiotemporal differences in presentation of CD8 T cell epitopes during hepatitis B virus infection","volume":"93","author":"Khakpoor","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2025.102004_bib45","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.smim.2025.102004_bib46","article-title":"Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC","author":"Tan","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.smim.2025.102004_bib47","article-title":"Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial","author":"Wu","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102004_bib48","article-title":"Genetically redirected HBV-specific T cells target HBsAg-positive hepatocytes and primary lesions in HBV-associated HCC","author":"Wan","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.smim.2025.102004_bib49","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cell.2015.03.005","article-title":"Immunosurveillance of the liver by intravascular effector CD8(+) T cells","volume":"161","author":"Guidotti","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.smim.2025.102004_bib50","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102004_bib51","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1084\/jem.20072076","article-title":"Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection","volume":"205","author":"Das","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2025.102004_bib52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nm.3856","article-title":"Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells","volume":"21","author":"Pallett","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2025.102004_bib53","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41577-024-01097-3","article-title":"Beyond exhaustion: the unique characteristics of CD8+ T cell dysfunction in chronic HBV infection","volume":"24","author":"Thimme","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2025.102004_bib54","article-title":"HBV-HCC treatment with mRNA electroporated HBV-TCR T cells","volume":"2","author":"Tan","year":"2021","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.smim.2025.102004_bib55","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/ijc.28311","article-title":"Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments","volume":"133","author":"Lee","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2025.102004_bib56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/jhep.2000.16470","article-title":"The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma","volume":"32","author":"Nagao","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.smim.2025.102004_bib57","doi-asserted-by":"crossref","first-page":"S433","DOI":"10.1016\/S0168-8278(25)01241-3","article-title":"THU-081 association of Tcell epitope spreading with the clinical efficacy of HBV-TCR T cell therapy for HBV-related HCC","volume":"82","author":"Tan","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.smim.2025.102004_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltae007","article-title":"A rapid method to assess the in vivo multi-functionality of adoptively transferred engineered TCR T cells","volume":"4","author":"Tan","year":"2024","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.smim.2025.102004_bib59","first-page":"767","article-title":"Liver sampling: a vital window into HBV pathogenesis on the path to functional cure","volume":"67","author":"Gill","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102004_bib60","article-title":"Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions","volume":"3","author":"Healy","year":"2021","journal-title":"J. Hep. Rep."},{"key":"10.1016\/j.smim.2025.102004_bib61","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad015","article-title":"Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood","volume":"3","author":"Lin","year":"2023","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.smim.2025.102004_bib62","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hep.31662","article-title":"Immunosuppressive drug-resistant armored T-cell receptor T cells for immune therapy of HCC in liver transplant patients","volume":"74","author":"Hafezi","year":"2021","journal-title":"Hepatology"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:47:09Z","timestamp":1773280029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532325000764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":62,"alternative-id":["S1044532325000764"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2025.102004","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2025.102004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102004"}}